Vesta, Inc.

Vesta, Inc. is a specialized medical device company dedicated to providing innovative solutions through the design and manufacturing of medical-grade thermoplastic polyurethane (TPU) for diverse healthcare applications. Founded in 1972 in Franklin, US, Vesta, Inc. has focused on the production of medical-grade thermoplastic polyurethane (TPU) used in various medical devices.

The company was acquired by The Lubrizol Corporation in August 2014, though financial terms of the transaction were not disclosed. The founders include Ashutosh Vyas and Steven Brown-Cestero, while Jignesh Dalal serves as the current CEO. The company has been involved in 2 deals to date, with the most recent deal occurring in 2014. Vesta, Inc.

specializes in high-quality medical-grade thermoplastic polyurethane (TPU), tailored for superior biostability and biocompatibility. The product range serves medical device designers and manufacturers, facilitating applications from short-term devices to long-term Class III solutions. Key brands include Carbothane™, Tecoflex®, and Pellethane®, utilized across sectors such as aesthetics, dental, diagnostics, and cardiovascular markets. Their global customer base primarily consists of medical device manufacturers who depend on Vesta's materials for device innovation.

Vesta, Inc. 's revenue is generated through B2B transactions with medical device manufacturers who require specialized TPUs and engineered thermoplastics. Their business model relies on client orders for customized materials, with key products like Carbothane™ and Tecoflex® forming a significant part of the revenue stream. Long-term supply agreements are common, ensuring consistent product availability to support client innovation in the medical device field.

Vesta, Inc. aims to expand its product offerings by introducing new medical-grade TPU formulations designed to meet emerging healthcare needs. The company is also targeting expansion into Asia-Pacific markets by 2025, focusing on enhancing its presence in regions with growing medical device demands. The recent acquisition by The Lubrizol Corporation is expected to facilitate these initiatives, providing the necessary resources and strategic alignment for growth.